Phase 3 N=15 Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
NLRC4-MAS · XIAP Deficiency
Primary: Prevention of Flares — 2.71; NA Weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=47 Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Familial Cold Autoinflammatory Syndrome (FCAS) · Familial Cold Urticaria · Muckle-Wells Syndrome (MWS)
Primary: Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS) — 2.4; 3.1; 2.1; 0.5 Units of a Scale — p=<.0001
Phase 2 N=11 Interleukin-1 Trap to Treat Autoinflammatory Diseases
Inflammation · Familial Mediterranean Fever · Still's Disease, Adult-Onset
Primary: Mean Change in Daily Scores — -3.09 units on a scale
Phase 3 N=17 Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Cryopyrin-associated Periodic Syndromes · Familial Cold Autoinflammatory Syndrome · Muckle-Wells Syndrome
Primary: Percentage of Participants Aged 4 Years or Younger With at Least One Complete Response at Week 56 — 94.1 Percentage of participants
N/A N=91 Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children
Respiratory Syncytial Virus Infection
Primary: Nasal Interferon (IFN)-a2 — 10; 26 pg/ml — p=0.04
Phase 2 N=14 A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Macrophage Activation Syndrome · Lymphohistiocytosis, Hemophagocytic · Arthritis, Juvenile
Primary: Incidence, Severity, Causality, and Outcomes of AEs (Serious and Nonserious) — 13; 6; 2; 10 Participants
Phase 3 N=166 Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Cryopyrin-Associated Periodic Syndromes · Familial Cold Autoinflammatory Syndrome · Muckle Wells Syndrome
Primary: The Number of Participants With Adverse Events (AEs), Death, Serious Adverse Events (SAEs), Discontinuation of Study Drug Due to an AE, Infections and Infestations and…
Phase 3 N=35 Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome
Muckle Wells Syndrome
Primary: Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part) — 0; 81.3 percent of participants
Phase 3 N=33 Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
Macrophage Activation Syndrome · Secondary Hemophagocytic Lymphohistiocytosis · Still Disease
Primary: Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab — 11; 4 Participants
Phase 2 N=17 MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
Acute Myelogenous Leukemia
Primary: < 5% Marrow Blast, no Circulating Peripheral Blasts and Neutrophil Count of > 1 x 10^9/L — 5 Participants
Phase 2 N=14 Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
Familial Mediterranean Fever
Primary: To Assess the Efficacy of Rilonacept in Decreasing the Number of Acute FMF Attacks. — 0.77; 2.00 number of attacks per month — p=0.027
Phase 3 N=17 Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Cryopyrin-associated Periodic Syndromes · Familial Cold Autoinflammatory Syndrome · Muckle-Wells Syndrome
Primary: The Percentage of Participants Without Disease Relapse as Determined by the Physician's Global Assessment of Autoinflammatory Disease Activity, Assessment of Skin…
Early Phase 1 N=18 Using MASL to Combat Oral Cancer
Squamous Cell Carcinoma of Head and Neck
Primary: Pre-treatment OSCC Morphology and PDPN Expression — 2.8; 3.4; 2.5 score on a scale from 1 to 5 — p=<0.05
N/A N=50 Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.
Transplantation, Lung
Primary: Association of Percentage of Mean Residual Expression (MRE%) of NFAT-related Cytokine Expression and Acute Cellular Rejection — 39.5; 41.7 percentage of mean residual…
N/A N=60 Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
Fatty Liver Disease · Type 2 Diabetes · Impaired Glucose Regulation
Primary: Change of Liver Fat Content in % — -20.5; -15.5; -7.6; -7.3 absolute fat content change in %
N/A N=17 Cytokines in Papillon-Lefèvre Syndrome
Papillon-Lefevre Disease
Primary: Serum Concentrations of Interleukin (IL)-1 Beta — 1100.00; 896.21; 65559; 45734 pg/ml
Phase 3 N=4 An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes
Periodic Fevers Syndrome
Primary: Number of Participants With Non-serious Adverse Events, Serious Adverse Events and Deaths — 1; 1; 0; 0 Participants
Phase 2 N=26 Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Systemic Mastocytosis, Aggressive (ASM) · Leukemia, Mast Cell · Hematological Non-mast Cell Lineage Disease (AHNMD)
Primary: Subjects With Clinical Response [Partial Response (PR) + Complete Response (CR)] — 25 participants
Phase 2 N=9 Canakinumab in Patients With Active Hyper-IgD Syndrome
Mevalonate Kinase Deficiency
Primary: Number of Flares Per Participant During Historical Period and Treatment Period — 5; 0 Number of flares
N/A N=131 Mechanisms of Severe Acute Influenza Consortium (MOSAIC)
Influenza
Primary: Number of Patients With Clinical Phenotype Presenting Also a Sequential Activation of Immune/Infammatory Pathways. — 131 Participants
Phase 3 N=73 MIS-C Comparative Effectiveness Study
Multisystem Inflammatory Syndrome-Children
Primary: Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization — 10; 10; 14 Participants
Phase 2 N=31 A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Coronary Heart Disease · Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Primary: Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model — 0.8602; 0.7558; 0.7002; 0.6657 ratio serum levels of IL-6 — p=0.0817
Phase 3 N=14 Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD
Adult Onset Still's Disease
Primary: Percentage of Participants Who Achieved Adapted American College of Rheumatology (ACR) 30 Response at Week 8 — 50.0 Percentage of participants
N/A N=12 p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma
Asthma
Primary: Differences in Activity and Downstream Activity of the p38 MAPK Activity in Macrophages or PBMCs Between Those From Severe and Non-Severe Asthmatics
Phase 2 N=30 Anakinra to Prevent Adverse Post-infarction Remodeling (2)
Acute Myocardial Infarction · Heart Failure
Primary: Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices — 1.5; 1.0 mL/m2 — p=<0.05
Phase 2 N=4 Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)
Familial Cold Autoinflammatory Syndrome
Primary: Ratio of Fold Change From Pre-challenge to the Highest Post-challenge Value of White Cell Count (WCC) Between Treatment and Screening Period — 0.82 ratio of fold change
N/A N=250 Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation
Colorectal Cancer
Primary: Comparisons of the Changes of Genera Prevotella by Mg Treatment vs. Placebo in Rectal Mucosa, Swab and Stool Samples — 0.108; 0.245; -0.076; 0.132 percentage of sample…
N/A N=21 Inflammatory Cytokine Quantification in Infants
Sepsis · Congenital Diaphragmatic Hernia · Neonatal Cardiopulmonary Failure
Primary: TNF-alpha, Baseline — 8.88 pg/mL
Phase 2 N=20 Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).
TNF-receptor Associated Periodic Syndromes (TRAPS)
Primary: Percentage of Participants With Complete or Almost Complete Response at Day 15 — 95 Percentage of participants
Phase 3 N=92 Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)
Asthma
Primary: Juniper Asthma Control Questionnaire (ACQ) Results — -0.15; -0.38 units on a scale